View More View Less
  • 1 Department of Inorganic Chemistry Medical University of Lublin, Chodźki 4a 20-093 Lublin, Poland
  • 2 Nicolaus Copernicus University, Faculty of Chemistry Gagarina 7, PL-87-100 Toruń, Poland
  • 3 Nicolaus Copernicus University, Wileńska 4, Toruń, Poland
  • 4 Medical University of Lublin, Głuska 2, 20-439 Lublin, Poland
Open access

Vortioxetine is a new drug against major depressive disorder with high affinity for a range of different serotonergic targets in the central nervous system. Therapeutic drug monitoring is an important tool for the clinical management of patients receiving a pharmacotherapy, particularly in psychiatry. For this reason, determination of drug concentration in biological fluids is important for a rational dosage of drugs. Rapid and reliable analytical assays are also required to detect and identify drugs of toxicological importance. For analysis of vortioxetine by high-performance liquid chromatography (HPLC), no procedures for its determination in saliva have been reported and there are only a few ones for its determination in serum. A sensitive and selective highperformance liquid chromatography with diode array detector (HPLC-DAD) or mass spectrometer (HPLC-MS) method was developed for the fast quantification of vortioxetine in human saliva and serum. The determination was performed on a Synergi Polar RP column in isocratic mode under the optimal mobile phase containing 70% methanol, 20% acetate buffer at pH 3.5, 10% double distilled water, and 0.025 M L−1 diethylamine.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1]

    L. Pehrson , S.C. Leiser, M. Gulinello, E. Dale, Y. Li, J.A. Waller, and C. Sanchez, Eur. J. Pharmacol., 753, 19 (2015)

  • [2]

    A. Mørk , L.P. Montezinho, S. Miller, C. Trippodi-Murphy, N. Plath, Y. Li, M. Gulinello, and C. Sanchez, Pharmacol. Biochem. Be., 105, 41 (2013)

    • Search Google Scholar
    • Export Citation
  • [3]

    J.B. Jensen , K.G. Jardin, D. Song, D. Budac, G. Smagin, C. Sanchez, and A.L. Pehrsonn, Eur. Neuropsychopharma., 24, 148 (2014)

  • [4]

    K.A. Connors , T.W. Valenti, K. Lawless, J. Sackerman, E.S. Onaivi, B.W. Brooks, and G.G. Goulde, Aquat. Toxicol., 151, 105 (2014)

  • [5]

    G. Chen , R. Lee, A.-M. Højer, J.K. Buchbjerg, M. Serenko, and Z. Zhao, Clin. Drug Investig., 33, 727 (2013)

  • [6]

    A.L. Pehrson , T. Cremers, C. Betry, M.G.C. van der Hart, L. Jørgensena, M. Madsen, N. Haddjeri, and B. Ebert, Eur. Neuropsychopharm., 23, 133 (2013)

    • Search Google Scholar
    • Export Citation
  • [7]

    C. Bétry , A. Etiévant, A. Pehrson, C. Sánchez, and N. Haddjeri, Prog. Neuro- Psychoph., 58, 38 (2015)

  • [8]

    H.J. Möller , Eur. Arch. Psychiatry Clin. Neurosci., 256, 476 (2006)

  • [9]

    P. Stenkrona , C. Halldin, and J. Lundberg, Eur. Neuropsychopharm., 23, 1190 (2013)

  • [10]

    G. Chen , R. Lee, A.-M. Højer, J.K. Buchbjerg, M. Serenko, and Z. Zhao, Clin. Drug Investig., 33, 727 (2013)

  • [11]

    E-m. Gu , C. Huang, B. Liang, L. Yuan, T. Lan, G. Hu, and H. Zhou, J. Chromatogr. B, 997, 70 (2015)

  • [12]

    C. Sanchez , K.E. Asin, and F. Artigas, Pharmacol. Ther., 145, 43 (2015)

  • [13]

    E-m. Gu , C. Huang, B. Liang, L. Yuan, T. Lan, G. Hu, and H. Zhou, J. Chromatogr. B, 997, 7074 (2015)

  • [14]

    C. Sanchez , K.E. Asin, and F. Artigas, Pharmacol. Ther., 145, 4357 (2015)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2020 0 14 29
Jul 2020 0 9 11
Aug 2020 0 10 19
Sep 2020 0 13 17
Oct 2020 0 9 13
Nov 2020 0 9 12
Dec 2020 0 0 0